Core Insights - Significant investors have adopted a bearish stance on Gilead Sciences, indicating potential insider knowledge of upcoming events [1] - The overall sentiment among large traders is 37% bullish and 50% bearish, with notable options activity observed [2] - The target price for Gilead Sciences is projected between $105.0 and $114.0 based on recent trading activity [3] Options Activity - In the last 30 days, Gilead Sciences has seen a mix of put and call options, with a total of $347,957 in puts and $145,672 in calls [2] - Noteworthy options trades include a bearish put sweep for $102.5K and a bullish call sweep for $34.1K, indicating varied investor sentiment [10] Company Overview - Gilead Sciences focuses on developing therapies for life-threatening infectious diseases, particularly in HIV and hepatitis [11] - The company has expanded into oncology through acquisitions, including CAR-T cell therapy and cancer treatments [11] Current Performance - Gilead Sciences is currently trading at $110.25, with a trading volume of 5,933,314 and a recent price decline of -0.81% [16] - Analysts have a consensus target price of $145.0, with one analyst maintaining an Overweight rating [13][14]